Skip to main content
Joseph Eron Jr., MD, Infectious Disease, Chapel Hill, NC, University of North Carolina Hospitals

JosephJEronJr.MD

Infectious Disease • Chapel Hill, NC

Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine

Join to view full profile

Dr. Eron is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Eron's full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical School
    Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1989 - 1992
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1984 - 1987
  • Harvard Medical School
    Harvard Medical SchoolClass of 1984

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1992 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults  
    Michael S Saag, Melanie A Thompson, Constance A Benson, Susan P Buchbinder, Joseph J Eron, Donna M Jacobsen, JAMA
  • Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-Uninfected Individuals: HPTN 077, a Phase 2a Randomized Controlled Trial  
    Susan H Eshleman, Joseph J Eron, Raphael J Landovitz, Myron S Cohen, Jeremy Sugarman, Mark A Marzinke, Craig W Hendrix, PLoS One
  • HIV Viral Suppression Trends over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study  
    Kenneth H Mayer, W Christopher Mathews, Michael J Mugavero, Katerina A Christopoulos, Richard D Moore, Benigno Rodriguez, Joseph J Eron, Michael S Saag, Mari M Kitahat..., Annals of Internal Medicine
  • Join now to see all

Lectures

  • 2013 Interscience Conference On Antimicrobial Agents & Chemotherapy 
    American Society For Microbology, Denver, Colorado - 9/10/2013

Press Mentions

  • Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
    Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIVFebruary 22nd, 2023
  • Mass General Brigham Sites Begin Phase 3 Trial Evaluating Monkeypox Treatment
    Mass General Brigham Sites Begin Phase 3 Trial Evaluating Monkeypox TreatmentOctober 19th, 2022
  • UCLA to Participate in Phase 3 Trial Evaluating Monkeypox Treatment
    UCLA to Participate in Phase 3 Trial Evaluating Monkeypox TreatmentSeptember 13th, 2022
  • Join now to see all

Grant Support

  • University Of North Carolina AIDS Clinical Trials Unit (Unc Actu)National Institute Of Allergy And Infectious Diseases2007–2012
  • Persistent CSF HIV Despite Successful CART: Viral Tropism, Drug Penetration AndNational Institute Of Mental Health2011
  • Clinical CoreNational Institute Of Allergy And Infectious Diseases2006–2011
  • Clinical Trial: Adult AIDS Clinical Trials Group Longitudinal Linked RandomizedNational Center For Research Resources2008
  • Chavi 001: Acute HIV-1 Infection Prospective Cohort StudyNational Center For Research Resources2007–2008
  • In Vitro Assessment Of Immunogenicity Of AT2 Inactivated Autologous VirionsNational Center For Research Resources2006–2008
  • Aactg 5175 - Drug Combinations For Initial Treatment Of HIV-1 Infected SubjectsNational Center For Research Resources2006–2008
  • Measure The Clearance Or Replication-Competent HIV-1 In Resting Memory Cd4+CellsNational Center For Research Resources2005–2008
  • PLAN For Obtaining Informed Consent To Use Stored Human Biological MaterialsNational Center For Research Resources2004–2008
  • Antiretroviral Therapy For Hiv-Infected Adults With Acute Infections:National Center For Research Resources2004–2008
  • Lamivudine PLUS Stavudine PLUS Abacavir PLUS Amprenavir/RitonaverNational Center For Research Resources2007
  • Regimen Simplification To Atazanavir/Ritonavir Alone As MaintenanceNational Center For Research Resources2006–2007
  • Longitudinal Assessment Of Acute HIV InfectionNational Center For Research Resources2005–2007
  • Adult AIDS Clinical Trials Group Longitudinal Linked Randomized TrialsNational Center For Research Resources2004–2007
  • Predictors Of Immunologic And Clinical Progression In Subjects With CD4+ CellNational Center For Research Resources2004–2006
  • Phenotypic Susceptibility (C12h/Ic50) On Antiretroviral Response To RitonavirNational Center For Research Resources2004–2006
  • Immunization Strategy With ALVAC-HIV Vcp1452 In HIV-1 SubjectsNational Center For Research Resources2004–2006
  • Adult Therapeutic Clinical Trials Program For AIDSNational Institute Of Allergy And Infectious Diseases2002–2006
  • Two Regimens Utilizing A Protease Inhibitor-Sparing Regimen VS NucleosideNational Center For Research Resources2005
  • Lopinavir/Ritonavir VS Gw433908 And Ritonavir VS Lopinavir/Ritonavir And Gw433National Center For Research Resources2004–2005
  • Two Regimens Utilizing A Protease Inhibitor-Sparing Regimen Vs. NucleosideNational Center For Research Resources2004
  • Treatment Of HIV With Stavudine, Didanosine, And NevirapineNational Center For Research Resources2004
  • ACTG 372: Virologic Success/Options For Virologic Failure In HIVNational Center For Research Resources2004
  • Phase I/II Study Of A Vrp VaccineNational Institute Of Allergy And Infectious Diseases2002
  • Treatment Of HIV W/ Stavudine, Didanosine, &NevirapineNational Center For Research Resources1999–2002
  • T 20 Administered To HIV 1 Adults By Continuous Subcutaneous InfusionNational Center For Research Resources1999–2002
  • Plasma Pharmacokinetics, &Antiviral Activity Of T 20 In HIVNational Center For Research Resources1999–2002
  • Long Term Safety Profile Of 141W94 In HIV SubjectsNational Center For Research Resources1999–2002
  • Intrasubject Variability Of Excretion Of HIV In Vaginal SecretionsNational Center For Research Resources1999–2002
  • HIV 1 Infected Subjects Response To Combinations Of DDI &HydroxyureaNational Center For Research Resources1999–2002
  • Four Drug Regimen VS Three Drug Regimen In HIV Infected SubjectsNational Center For Research Resources1999–2002
  • Delavirdine Mesylate In Triple &Quadruple Combinations In HIV 1National Center For Research Resources1999–2002
  • Combination Therapy W/ 1592u89, 141w94, &Dmp 266 In HIVNational Center For Research Resources1999–2002
  • Abt378 &Ritonavir In Protease Inhibitor Experienced HIV PatientsNational Center For Research Resources1999–2002
  • Zidovudine, Lamivudine And Indinavir In HIV PatientsNational Center For Research Resources1998–2002
  • Zerit PLUS Videx Versus Retrovir PLUS Epivir In HIV Seropositive SubjectsNational Center For Research Resources1998–2002
  • ZDV Resistant HIV Virus In Women And Evaluation Of Long Term EffectivenessNational Center For Research Resources1998–2002
  • Virologic Success/Options For Virologic Failure In HIVNational Center For Research Resources1998–2002
  • Virologic And Immunologic Activity Of Continued LamivudineNational Center For Research Resources1998–2002
  • Study Of Indinavir Sulfate (IDV) And 1592689 In HIV InfectionNational Center For Research Resources1998–2002
  • Study Of 141w94/Vx-478 Monotherapy Versus 141w9/VxNational Center For Research Resources1998–2002
  • Soft Gelatin Capsule Of Sqvsgc In Combination With Ritonavir Or NelfinNational Center For Research Resources1998–2002
  • Phase I/II Screening Trial To Identify Potential Partner CompoundsNational Center For Research Resources1998–2002
  • Intrasubject Variability Of Excretion Of HIV In Semen Over TimeNational Center For Research Resources1998–2002
  • Epivir, Retrovir And Protease Inhibitor Versus 3TC With Protease InhibitorNational Center For Research Resources1998–2002
  • Comparison Of Virologic Efficacy Of Nelfinavir AND/OR Dmp-266National Center For Research Resources1998–2002
  • Abt378/Ritonavir In Combination With Reverse Transcriptase Inhibitors In HIVNational Center For Research Resources1998–2002
  • 141w94/Vx-478 PLUS 3TC PLUS ZDV Or Indinavir PLUS Nevirapine PLUS 3TC In HIVNational Center For Research Resources1998–2002
  • Three Fixed Doses Of Delavirdine With ZDV VS ZDV Alone In HIV InfectionNational Center For Research Resources1997–2002
  • Study Of Viracept In Combination With ZDV + 3TC VS AZT + 3TC In HIV PatientsNational Center For Research Resources1997–2002
  • L-735,524 And Zidovudine VS L-735,524 VS Zidovudine In HIV InfectionNational Center For Research Resources1997–2002
  • Hydroxyurea Alone &In Combination W/ DDI VS DDI In Patients With HIV InfectionNational Center For Research Resources1997–2002
  • Mk639 Administered In Combination With Zidovudine &3tc VS ZDV &3tc VS Mk639National Center For Research Resources1996–2002
  • Zerit PLUS Videx Versus Retrovir PLUS Epivir In HIV PTSNational Center For Research Resources2000
  • Viracept In Combination W/ ZDV + 3TC VS AZT + 3TC In HIV PTSNational Center For Research Resources2000
  • STC VS Dlv/Idv/Zdv Or D4T In HIV InfectionNational Center For Research Resources2000
  • Saquinavir/Ritonavir Or Nelfinavir/Delavirdine/Or Adefovir Dipivoxilin In HIV PTSNational Center For Research Resources2000
  • Recombinant Human Interleukin-12 In HIV Infected PTSNational Center For Research Resources2000
  • Protocol For HIV Infected Adults W/ Prior T-20 TreatmentNational Center For Research Resources2000
  • Pharmacokinetics Of Oral DAPD In HIV-1 Infected PTSNational Center For Research Resources2000
  • Mk639 In Combination W/ Zidovudine &3tc VS ZDV &3tc VS Mk639National Center For Research Resources2000
  • L-735,524 &Zidovudine VS L-735,524 VS Zidovudine In HIV InfectionNational Center For Research Resources2000
  • Indinavir Sulfate W/ Ritonavir In HIV Infected PatientsNational Center For Research Resources2000
  • Indinavir Sulfate (Idv), Dmp-266 &1592689 In HIV InfectionNational Center For Research Resources2000
  • Hydroxyurea In HIV PTS On Potent Antiretroviral TherapyNational Center For Research Resources2000
  • Hydroxyurea &In Combination W/ DDI VS DDI In HIV InfectionNational Center For Research Resources2000
  • Effects Ofamprenavir, Abacavir &3tc In HIV Infected PTSNational Center For Research Resources2000
  • Dynamics Of Hepatitis C Infection In PTS W/ HCV &HivNational Center For Research Resources2000
  • Ddl/D4t/Hu VS Ddl/D4t/Efv VS Protease Inhibitor In HIV PTSNational Center For Research Resources2000
  • Azithromycin Prophylaxis For Primary Prevention Of MACNational Center For Research Resources2000
  • Antiviral Activity Of T-1249 In HIV-1 Infected AdultsNational Center For Research Resources2000
  • Abt378/Ritonavir W/ Reverse Transcriptase Inhibitors In HIVNational Center For Research Resources2000
  • 141w94/Vx-478/ 3tc/ ZDV Or Indinavir/ Nevirapine/ 3TC In HIVNational Center For Research Resources2000
  • Core--Behavioral/ClinicalEunice Kennedy Shriver National Institute Of Child Health &Human Development1998–2000
  • Virologic Response To New Nucleoside Regimens After Prolonged ZDV Or DDI In HIVNational Center For Research Resources1997–1999
  • Virologic And Immunologic Effects Of ZDV VS D4T VS ZDV In HIV Infected PatientsNational Center For Research Resources1997–1999
  • Study Of Viracept As Monotherapy In HIV Positive PatientsNational Center For Research Resources1997–1999
  • Phase III Ritonavir Long Term Treatment Trial In HIV (Abbott M96-432)National Center For Research Resources1997–1999
  • Influence Of Risk Status For Disease Progression To Antiretroviral In HIVNational Center For Research Resources1997–1999
  • Differences Among Various Zdv/Ddi Regimens On Viral Burden In HIV InfectionNational Center For Research Resources1997–1999
  • Delavirdine Mesylate Treatment In Triple Combination For HIV-1+ PatientsNational Center For Research Resources1997–1999
  • ACTG 320--Idu With OPEN Label ZDV And 3TC In Subjects With HIV InfectionNational Center For Research Resources1997–1999
  • ACTG 306--3tc-Tm In Combination With Zdv, D4T Or DDI VS Monotherapy In HIVNational Center For Research Resources1997–1999
  • ACTG 193, Version 1.0--Nucleoside Therapy For HIV TreatmentNational Center For Research Resources1997–1999
  • ACTG 244--Zidovudine VS ZDV And DDI VS ZDV And DDI NevirapineNational Center For Research Resources1996–1999
  • MN Rgp120/Hiv-1 Vaccine Compared W/Placebo In HIV-1 Seropositive SubjectsNational Center For Research Resources1997
  • Delavirdine Mesylate With Didanosine VS DDI Alone In HIV InfectionNational Center For Research Resources1997
  • 3TC Monotherapy VS AZT Or ZDV Monotherapy VS 3TC In HIV-1 InfectionNational Center For Research Resources1997
  • Chronic Nevirapine Dosing In HIV-1 Infected PatientsNational Center For Research Resources1996–1997
  • Virologic Response To New Nucleoside Regimens After Prolonged ZDVNational Center For Research Resources1996
  • Phase II Double Blind Exploratory Study To Evaluate Zdv/Ddi--Actg 276National Center For Research Resources1996
  • Influence Of Risk Status For Disease Progression On Response To New RegimensNational Center For Research Resources1996
  • Delvirdine Mesylate Treatment In Triple Combination For HIV+ PatientsNational Center For Research Resources1996
  • Anti-Hiv Activity Of Delavirdine Mesylate--Actg 260National Center For Research Resources1996
  • Three Fixed Doses Of Delavirdine With ZDV VS ZDV Alone In HIVNational Center For Research Resources1995–1996
  • Study Of Delavirdine Mesylate With Didanosine VS DDI AloneNational Center For Research Resources1995–1996
  • Monotherapy VS Combination Therapy W/ Nucleosides Analogues In HIV Infected PTSNational Center For Research Resources1995–1996
  • MN Rgp120/Hiv 1 Vaccine Compared With Placebo In HIV 1 Seropositive SubjectsNational Center For Research Resources1995–1996
  • L-735,524 And Zidovudine VS L-735,524 VS ZidovudineNational Center For Research Resources1995–1996
  • Assessment Of Two Orally Administered Dosing Regimens ABT 538 In HIVNational Center For Research Resources1995–1996
  • ACTG 241--Zdv, DDI, And Double Blinded NVP VS ZDV And DDINational Center For Research Resources1995–1996
  • ACTG 193--Nucleoside Therapy For HIV TreatmentNational Center For Research Resources1995–1996
  • 3TC Monotherapy VS AZT Or ZDV Monotherapy VS 3TC Administered ConcurrentlyNational Center For Research Resources1995–1996
  • Study Of Hpmpc For The Treatment Of Peripheral Cytomegalovirus In AIDS PatientsNational Center For Research Resources1995
  • ACTG 244--Zidovudine VS ZDV And DDI ZDV And DDI NevirapineNational Center For Research Resources1995
  • Quantitation Of Isolation Of Drug Resistant HIV In VitroNational Institute Of Allergy And Infectious Diseases1991

Hospital Affiliations

Dr. Joseph Eron, Dr. Joseph Eron, MD, Dr. J Eron, Dr. Joseph J Eron